TARS
Tarsus Pharmaceuticals, Inc.Company Information
- Company Name
- Tarsus Pharmaceuticals, Inc.
- CIK
- CIK0001819790
- Category
- Large accelerated filer
- Ticker: Exchange
- TARS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- TARS
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-12-15
- Last sale
- 2026-09-15
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 198,443
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 46,785,078
- Shares outstanding
- 43,393,643
- Ownership
- 107.82%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 9.84%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents Fair Value Disclosure | 205 | 102 | 184 | 113 | 97 | 176 | 95 | 176 | 181 | 194 | 225 | 227 | ||||||
| Restricted Cash Current | 0 | 0 | 1 | - | - | - | 0 | - | - | - | - | - | ||||||
| Marketable Securities Current | 245 | 287 | 234 | 289 | 284 | 232 | 197 | 141 | 142 | 105 | 2 | 20 | ||||||
| Accounts Receivable Net Current | 96 | 100 | 85 | 73 | 58 | 62 | 47 | 29 | 30 | 30 | 17 | 5 | ||||||
| Inventory Net | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 2 | 4 | 3 | 0 | ||||||
| Other Receivables Net Current | 2 | 17 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Prepaid Expense Current | 10 | 27 | 13 | 22 | 29 | 6 | 15 | 7 | 6 | 7 | 8 | 6 | ||||||
| Assets Current | 562 | 537 | 523 | 502 | 474 | 481 | 357 | 357 | 363 | 341 | 256 | 259 | ||||||
| Restricted Cash Noncurrent | 2 | 2 | 2 | 3 | 3 | 3 | 3 | - | - | - | 0 | - | ||||||
| Inventory Noncurrent | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | - | 0 | - | ||||||
| Property Plant And Equipment Net | 20 | 18 | 12 | 6 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 2 | ||||||
| Intangible Assets Net Excluding Goodwill | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 9 | 4 | 4 | 4 | 4 | ||||||
| Operating Lease Right Of Use Asset | 10 | 10 | 10 | 10 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
| Long Term Investments | 7 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 0 | 1 | 0 | ||||||
| Other Assets Noncurrent | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | ||||||
| Assets | 611 | 581 | 562 | 535 | 495 | 501 | 377 | 376 | 377 | 349 | 265 | 268 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 40 | 24 | 16 | - | - | - | 9 | - | - | - | - | - | ||||||
| Employee Related Liabilities Current | 12 | 9 | 18 | 14 | 12 | 10 | 16 | 11 | 8 | 6 | 13 | 8 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 124 | 111 | 102 | 103 | 79 | 76 | 55 | 55 | 44 | 37 | 24 | 15 | ||||||
| Liabilities Current | 176 | 144 | 136 | 117 | 90 | 86 | 81 | 66 | 52 | 43 | 37 | 23 | ||||||
| Long Term Debt Noncurrent | 73 | 73 | 72 | 72 | 72 | 72 | 72 | 72 | 72 | 30 | 30 | 30 | ||||||
| Other Liabilities Noncurrent | 16 | 16 | 11 | 10 | - | - | 0 | 1 | 1 | 2 | 2 | 2 | ||||||
| Liabilities | 264 | 232 | 219 | 199 | 162 | 158 | 152 | 139 | 125 | 74 | 69 | 55 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 799 | 783 | 770 | 753 | 738 | 728 | 585 | 574 | 566 | 556 | 442 | 416 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -452 | -434 | -427 | -418 | -406 | -385 | -360 | -337 | -314 | -280 | -245 | -203 | ||||||
| Stockholders Equity | 347 | 349 | 343 | 335 | 333 | 342 | 225 | 237 | 252 | 275 | 197 | 214 | ||||||
| Liabilities And Stockholders Equity | 611 | 581 | 562 | 535 | 495 | 501 | 377 | 376 | 377 | 349 | 265 | 268 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 43 | 43 | 43 | 42 | 42 | 42 | 38 | 38 | 38 | 38 | 34 | 33 | ||||||
| Shares Outstanding | 43 | 43 | 43 | 42 | 42 | 42 | 38 | 38 | 38 | 38 | 34 | 33 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTarsus Pharmaceuticals, Inc. (TARS) — SEC Financial Statements & Analysis
Tarsus Pharmaceuticals, Inc. (TARS) is a biological products, (no diagnostic substances) company, incorporated in DE. Tarsus Pharmaceuticals, Inc. trades on Nasdaq as: TARS. Tarsus Pharmaceuticals, Inc. (TARS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Tarsus Pharmaceuticals, Inc. carries a market cap of $2.73B, a P/E ratio of -58.77x, a P/B ratio of 7.88x, a P/S ratio of 4.50x, an enterprise value of $2.60B, and an EV/EBITDA multiple of -55.14x. On profitability, it posts a gross margin of 93.28%, an operating margin of -8.00%, a net margin of -7.67%, a Return on Equity (ROE) of -13.68%, a Return on Assets (ROA) of -8.40%, and a Return on Invested Capital (ROIC) of -16.32%. Per share, it reports EPS of $-1.07, diluted EPS of $-1.07, free cash flow per share of $1.29, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 105.17% year-over-year, net income growth of -49.48% year-over-year, and EPS growth of -50.68% year-over-year. On the balance sheet, it maintains a current ratio of 3.20x, a quick ratio of 3.12x, working capital of $386.24M, a debt-to-equity ratio of 0.76x, a debt ratio of 0.43, an interest coverage ratio of -5.54x, free cash flow of $56.00M (TTM), and net debt of $-133.83M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.73B
- P/E TTM
- -58.77x
- EPS TTM
- $-1.07
- P/B TTM
- 7.88x
- ROE TTM
- -13.68%
- ROA TTM
- -8.40%
- Debt To Equity
- 0.76x
- Free Cash Flow TTM
- $56.00M
- Net Revenue TTM Growth 1Y
- 105.17%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Tarsus Pharmaceuticals, Inc. in?
Tarsus Pharmaceuticals, Inc. (TARS) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does TARS trade on?
Tarsus Pharmaceuticals, Inc. (TARS) trades on the Nasdaq.
Where is Tarsus Pharmaceuticals, Inc. incorporated?
Tarsus Pharmaceuticals, Inc. is incorporated in DE.
When was Tarsus Pharmaceuticals, Inc. (TARS)'s most recent SEC filing?
Tarsus Pharmaceuticals, Inc. (TARS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is TARS's market cap?
Tarsus Pharmaceuticals, Inc. (TARS) has a market capitalization of $2.73B as of 2026-06-30.
What is TARS's EPS (earnings per share)?
Tarsus Pharmaceuticals, Inc. (TARS)'s trailing twelve month EPS is $-1.07 as of 2026-06-30.
What is TARS's ROE (return on equity)?
Tarsus Pharmaceuticals, Inc. (TARS)'s trailing twelve month Return on Equity (ROE) is -13.68% as of 2026-06-30.
What is TARS's ROA (return on assets)?
Tarsus Pharmaceuticals, Inc. (TARS)'s trailing twelve month Return on Assets (ROA) is -8.40% as of 2026-06-30.
What is TARS's ROIC (return on invested capital)?
Tarsus Pharmaceuticals, Inc. (TARS)'s trailing twelve month Return on Invested Capital (ROIC) is -16.32% as of 2026-06-30.
What is TARS's EV/EBITDA?
Tarsus Pharmaceuticals, Inc. (TARS)'s trailing twelve month EV/EBITDA is -55.14x as of 2026-06-30.